Member Info for David1951c

The news of NED appointment yesterday is very positive and was probably the main factor of yesterday's rise. Joe Eid has the contacts to make things happen. "my extensive experience of the development and use of biomarkers in oncology to drive forward the Company's strategy and to using my network of pharma industry, clinical and academic thought leaders to accelerate the Company's commercial development."

On top of today's news, Deltic have applied for additional blocks in 33rd round which closes tomorrow. It is expected that the first licences will be awarded from the second quarter of 2023.
The NSTA intends to award blocks in tranches with those that have the potential to produce quickly taking precedence, subject to any requirement for further environmental appropriate assessments.
Hopefully Deltic have shown they have the potential.

As I holder I am very disappointed in the SP even against the wider backdrop and depressed market. Half year loss was over £11m and revenue only £1.4m. With cash of £16m it seems further funding will be required within 6 months. Equity finding at such a low price would be even more detrimental. Risk is significant so there may be a reluctance to invest more until position becomes clearer. Any views on revenue in full year?

Agree huge potential and there could be a major SP uplift with P3 agreement hopefully not too far away. However, the company is not cash rich and is funded to mid 2023 only. There is a risk that a delay in agreement could lead to another fund raise. I truly hope not as have over 100k shares and steadily building a bigger position.

SP is a disappointment to say the least but progress continues and there are good grounds for optimism.
1. Funds available to last well into 2024
2. Bailie Gifford took over 5% at 80p share price
3. Company increasingly on the radar with regular positive updates
4. Commercialisation activities are on-going and stepping up
Patience will be rewarded and most importantly a further equity fund raise is unlikely.

Presumably as the $10m is "illustrative" it is wishful thinking and not based on any contractual milestones as no deals have yet been struck. If this were to happen and it equates to 18 months funding, that would be a major boost. I hold 100k shares but cannot risk any additional investment without there being a clearer path to P3 and future commercialisation.

On the face of it some good news in cost containment and AGL say no impact on the business and R&D. The cash runway is materially extended but many have expectations of commercialisation within the next 12 months making future funding a non-issue. Hard to judge if the RNS is really positive but SP reaction is not as expected.

It does seem there is a large seller as SP drop has been relentless lately. Another large sell today would possibly confirm that. Three months ago AGL raised at 80p and nothing seems to have happened to cause the drop. It is a great entry or top up point but I suspect it could go lower if the large seller continues to off load. With so much going on have been adding in small 2500 purchases.

Like everybody I am well down but not too heavily invested. IES seems a good company with good products in a decarbonising world and there should be a very significant increase in demand. However, will it come quickly enough given the cash burn. I held off buying more to average down because the company will struggle unless there is a major investor or grants. I am awaiting to read the presentation and Q&A more importantly before deciding.
Problem for me is that cash went down £10m in six months and with £16m left that is one more year. The further issue is that any equity fund raise would almost certainly be sub 20p unless some big orders come in within six months.

This is a great company with leading products that could become huge in demand. Funding is the issue and I will not buy more at this stage. I am a small investor anyway but have been bitten too many times by dilution.
Annualised loss from half year figures is over £5m and cash at last count was £6.3m. A fund raise or other funding solution will be required within 12 months. A cornerstone £10m investment with minimal SP dilution would be a way forward but I never hold out too much hope. I will hold but not add for now.

AMTE has great potential especially with so much going on in numerous areas. However current market conditions are such that PIs are less inclined to invest on potential alone when the big prize is a few years away for the Dundee plant (2025). There are other development areas including JV in Australia and technology is market leading.
As such AMTE is worth multiples but SP will be stodgy until funding position for Dundee becomes clearer including Scottish Enterprise grants. To expand will require more funds which would be best met by a cornerstone investment.
Awaiting the full year results to make a clearer assessment but worth adding steadily.
Possible take over target due to great products and near term commercialisation.

....... cannot be guessed at. No-one knows. DX have been suspended since January and even changed auditors.
The issues for RevB look significant as relate to numerous areas. Balance Sheet items are critical and write downs could be material but again no-one knows.

RNS 28 June said next step will be TFS but unclear how long this might take. Have any indications been given?
One would hope the work had been under way for some time and could be completed quickly but once again RBW do not seem dynamic enough in making progress.

It is quite surprising that the auditors have raised potential issues on stock valuation, bad debt provisions and revenue recognition since 2 August which is what RNS says. In most audits some or all of this ought to have become apparent earlier on in the audit especially if possibly material. If the balance sheet is impacted won;t this possibly increase the net debt?

Agree this is very risky. AIM Rule 19 requires that audited accounts are prepared within six months of the year end. There is a risk the shares could be suspended and could take some time to resolve the issues - look at DX. Worth a small punt for the gambling instinct so took 35k.

Further fund raising shouldn't be necessary this year. Best thing for future fund raising would be for Wood to take 1or 2 bn to raise up to £10m. Small change for them but life changing for EQT.

Some on here have huge holdings and dwarf mine. In throwing out old copies of Shares Mag recently, I came across December 2017 edition which says "Drug developer ImmuPharma is expecting phase III results in first quarter of 2018 for lupus treatment Lupuzor. Analysts speculate the drug could hit multi billion dollar annual sales if the tests are successful and the drug gets approved by the regulators.
So this is a good time to buy but the risk reward remains high especially the reward side.

The delays and lack of real clarity on the issues with competing this project are a concern. I have invested in EQT over the last 5 years and have a decent holding of over 7m at an average of 0.45p. I don't think the company are being open and honest about NF and overall I have lost confidence in the Board's ability to deliver generally. I still believe there should be a good outcome as there are many projects and many partners who want the company to succeed. If I lose trust in the company I will sell some without losing too much money.
EQT have a significant stake in NF and must be able to get this to completion. Lack of clear updates and timescales suggests it is seriously drifting. However I still hope for concrete news in the next 4 weeks.

Agree with C909 that the current position is not good enough. EQT need to show some concrete progress and most of all get one new plant up and running asap. Too much effort on a pipeline and not getting the timelines achieved. Focus on delivering not holding more discussions with more potential partners. Frustrated PIs are selling and whilst AIM pricing methodology is not fit for purpose the reality is the SP that has dropped due to lack of concrete progress and concerns on funding.
I am fortunate as holding 7m shares at 0.50p average but it is so disappointing to see the continual drift downwards. The Board and management must know what is behind the SP drop - lack of real progress and make excuses that after a while are not convincing.

Further drop today of 6% on only a small volume of sells (£50k) with a SP drop of 70% in last 9 months. Considering the company is well funded the drop is hard to fathom. Total cash, cash equivalents and short-term investments were $246.3 million as of March 31, 2022.
AIM volatility and lack of interest are a real turn off for IIs and deter PIs too. Doesn't make sense but a good time to buy and top up. Other bios are in a similar position but it is tough to take and must be a big blow to management as well.